

Credit: Getty Images

Editorials

V

EDITOR'S

Contents

197 The importance of authorship integrity in scientific publications within healthcare and hospital pharmacy E Castellana

199 Hospital pharmacists in antimicrobial stewardship programmes: a call for harmonised action across Europe D Mengato, P van der Linden, G Berti, E Barbieri, R M Van Hest, D Donà

Systematic review

202 Costs, challenges and opportunities of decentralised chimeric antigen receptor T-cell production: a literature review and clinical experts' interviews

G Stemer, T Mittermayr, P Schnell-Inderst, C Wild

Original research

209 Patient safety culture and medication safety in European intensive care units: a focus group study

R Laaksonen, A R Burch, J Lass, S McCarthy, M Howlett, V Silvari

220 Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-vear analysis

D Gómez Costas, A Ribed, A Gimenez-Manzorro, I Garutti, F J Sanz, I Taladriz-Sender, S Herrero, Y Rioja, A Carrillo, A Herranz, M Sanjurjo-Saez

226 Clinical pharmacy as a guarantee of safety in times of crisis: evolution and relevance of the continued presence of clinical pharmacists in frontline medical units during the first wave of COVID-19

A Tanty, E Vitale, D Lombardo-Duron, A Grevy, P Gibert, C Chapuis, C Chevallier-Brilloit, B Allenet, P Bedouch, S Chanoine

Analysis of the use of antibiotics by 232 AWaRe categories during the COVID-19 pandemic in hospitals across Scotland: a national population-based study E Proud, T Mueller, K Gronkowski, A Kurdi,

N Platt, A Morrison, M Bennie, W Malcolm

236 Comparative analysis of the prevalence 3-HIT concept in people living with HIV and seronegative patients with chronic conditions. Cross-3HIT Project. E Contreras Macías, J M Espina Lozano,

M D Cantudo-Cuenca, M d l A Robustillo-Cortés, E Gabella-Bazarot, R Morillo-Verdugo

241 Development and prioritisation of policy recommendations for medication safety improvement for intensive care units: a European Association of Hospital Pharmacists Special Interest Group Delphi Study

M Howlett, S McCarthy, V Silvari, B D Franklin, R Laaksonen, On behalf of the EAHP Special Interest Group for the investigation of medication errors in intensive care units

250 Enhancing pharmaceutical decision support system: evaluating antithrombotic-focused algorithms for addressing drug-related problems A Potier, M Ade, B Demoré, E Divoux, A Dony,

E Dufay

259 Adverse drug effect in the context of drug shortage: the CIRUPT prospective study from the French pharmacovigilance network

D Bourneau-Martin, A Grandvuillemin, M Babin, C Mullet, H Said, M Cellier, H Geniaux, S Gautier, M Beurrier, G Veyrac, L Lagarce, M-L Laroche, M Briet

266 Complementary and alternative medicine in HIV care: frequency of consumption, risks and interactions with antiretroviral therapy E Colominas-González, M De Antonio,

M Masip, M T Martin Conde, G Cardona, D Fresán Restituto, D Comas, M A Roch, B López, F I Torres-Bondia, A Retamero, H Knobel, S Luque

272 Evaluation of the stability of aciclovir in OPEN ACCESS elastomeric infusion devices used for outpatient parenteral antimicrobial therapy F B Sime, S Wallis, C Jamieson, T Hills,

M Gilchrist, M Santillo, R A Seaton, F Drummond, J Roberts, on behalf of the BSAC **OPAT Drug Stability Testing Programme**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



C O P E

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org



Contents

278 Cleaning validation for blister packaging machines in hospital-supplying pharmacies D Fenske, L Zerrenner, S Zergiebel

Hands on medicines information

283 How can oral second-line anti-tuberculosis medications be administered to an extremely preterm neonate? *TTNgo, CLau*

Case report

286 Budd-Chiari syndrome after BNT162b2 mRNA vaccination: two case reports *L Lipszyc, L Triquet, B Giguet, O Lambotte, S Babai*

Short reports

289 Errors in prescribing injectable anticancer drugs: benefits of a pharmaceutical long-term monitoring to improve patient safety in a European comprehensive cancer centre *M Dupre, L Escalup, S Blondeel-Gomes, P Vaflard, R Desmaris, P Cottu, A Acramel*

293 Budget impact analysis: comparing the costs of nusinersen and risdiplam in the treatment of type 3 spinal muscular atrophy patients

M E Uda, M Rivano, L Aledda, M A Maioli, F Lombardo

295 Liquid antimicrobials: a national analysis of critical shortages N Riesenhuber, M Krauss, K Moβburger, C Gradwohl, G Stemer